News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Start mfn-cus-aladote

Press releases

July 13, 2022

Egetis receives positive opinion on orphan designation for Aladote® from the European Medicines Agency for the Prevention of Acute Liver Failure

January 11, 2022

Egetis Therapeutics gets Notice of Intent to Grant for a new European patent for a combination therapy with Aladote

Regulatory

August 19, 2021

Emcitate development program progressing according to plan

October 14, 2020

Design of pivotal Phase IIb/III study for Aladote® finalized after completed interactions with FDA, EMA and MHRA

January 8, 2020

PledPharma to initiate one pivotal Phase II/III study with Aladote® for marketing authorisation application in both US and EU

July 15, 2019

The Lancet EBioMedicine publishes Aladote® study results

July 11, 2019

Aladote® – regulatory interactions

April 12, 2019

PledPharma’s drug candidate Aladote® is highlighted at one of the largest liver conferences globally

March 26, 2019

Data from the POP study support further development of Aladote® as a new treatment option for reducing liver damage due to paracetamol overdose

Regulatory

March 18, 2019

PledPharma’s drug candidate Aladote® granted Orphan Drug Designation

Share

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: info@egetis.com